4‘-(Ferrocenyl)-2,2‘:6‘,2‘ ‘-terpyridine (Fctpy) and 4‘-(4-pyridyl)-2,2‘:6‘,2‘ ‘-terpyridine (pytpy) were prepared from the corresponding ferrocene- and pyridinecarboxaldehyle and 2-acetylpyridine using the Krohnke synthetic methodology. Metal complexes, [M(Fctpy)2](PF6)2 (M = Ru, Fe, Zn), [Ru(tpy)(Fctpy)](PF6)2 (tpy = 2,2‘:6‘,6‘ ‘-terpyridine), and [Ru(pytpy)2](PF6)2 were prepared and characterized. Cyclic voltammetric analysis indicated RuIII/II and ferrocenium/ferrocene redox couples near expected potentials (RuIII/II ∼1.3 V and ferrocenium/ferrocene ∼0.6 V vs Ag/AgCl). In addition to dominant πtpy → πtpy* UV absorptions near 240 and 280 nm and dπ Ru → πtpy* MLCT absorptions around 480 nm, the complexes [Ru(Fctpy)2](PF6)2 and [Ru(tpy)(Fctpy)](PF6)2 exhibit an unusual absorption band around 530 nm. Resonance Raman measurements indicate that this band is due to a 1[(d(π)Fc)6] → 1[(d(π)Fc)5(π*tpy Ru)1] transition. For [Ru(Fctpy)2](PF6)2 and [Ru(tpy)(Fctpy)](PF6)2, excited-state emission and lifetime measurements indicated an upper-limit emission quantum yield of 0.003 and an upper-limit emission lifetime of 0.025 μs. The influence of the ferrocenyl site on excited-state decay is discussed, and an excited-state energy level diagram is proposed.

Study Objectives. To evaluate the effect of mind-body interventions (MBI) on sleep. Methods. We reviewed randomized controlled MBI trials on adults (through 2013) with at least one sleep outcome measure. We searched eleven electronic databases and excluded studies on interventions not considering mind-body medicine. Studies were categorized by type of MBI, whether sleep was primary or secondary outcome measure and outcome type. Results. 1323 abstracts were screened, and 112 papers were included. Overall, 67 (60%) of studies reported a beneficial effect on at least one sleep outcome measure. Of the most common interventions, 13/23 studies using meditation, 21/30 using movement MBI, and 14/25 using relaxation reported at least some improvements in sleep. There were clear risks of bias for many studies reviewed, especially when sleep was not the main focus. Conclusions. MBI should be considered as a treatment option for patients with sleep disturbance. The benefit of MBI needs to be better documented with objective outcomes as well as the mechanism of benefit elucidated. There is some evidence that MBI have a positive benefit on sleep quality. Since sleep has a direct impact on many other health outcomes, future MBI trials should consider including sleep outcome measurements.

Background: Polysomnography is associated with changes in sleep architecture called the first-night effect. This effect is believed to result from sleeping in an unusual environment and the technical equipment used to study sleep. Sleep experts hope to decrease this variable by providing a more familiar, comfortable atmosphere for sleep testing through hotel-based sleep centers. In this study, we compared the sleep parameters of patients studied in our hotel-based and hospitalbased sleep laboratories. Methods: We retrospectively reviewed polysomnograms completed in our hotel-based and hospital-based sleep laboratories from August 2003 to July 2005. All patients were undergoing evaluation for obstructive sleep apnea. Hospital-based patients were matched for age and apnea-hypopnea index with hotel-based patients. We compared the sleep architecture changes associated with the first-night effect in the two groups. The associated conditions and symptoms listed on the polysomnography referral forms are also compared. Results: No significant differences were detected between the two groups in sleep onset latency, sleep efficiency, REM sleep latency, total amount of slow wave sleep (NREM stages 3 and 4), arousal index, and total stage 1 sleep. conclusions: This pilot study failed to show a difference in sleep parameters associated with the first-night effect in patients undergoing sleep studies in our hotel and hospital-based sleep laboratories. Future studies need to compare the first-night effect in different sleep disorders, preferably in multi-night recordings.

The US health care system has a long history of discouraging the creation and maintenance of meaningful relationships between patients and providers. Fee-for-service payment models, the 1-directional, paternalistic approach of care providers, electronic health records, anddocumentation requirements, all present barriers to the development of meaningful relationships in clinic visits. As patients and providers adopt and experiment with telemedicine and other systems changes to accommodate the impact of Coronavirus disease 2019, there is an opportunity to reimagine visits entirely—both office-based and virtual—and leverage technology to transform a unidirectional model into one that values relationships as critical facilitators of health and well-being for both patients and providers.

No abstract